Predictors of mortality in HIV-1 infected children on antiretroviral therapy in Kenya: a prospective cohort

Dalton C Wamalwa, Elizabeth M Obimbo, Carey Farquhar, Barbra A Richardson, Dorothy A Mbori-Ngacha, Irene Inwani, Sara Benki-Nugent, Grace John-Stewart, Dalton C Wamalwa, Elizabeth M Obimbo, Carey Farquhar, Barbra A Richardson, Dorothy A Mbori-Ngacha, Irene Inwani, Sara Benki-Nugent, Grace John-Stewart

Abstract

Background: Among children, early mortality following highly active antiretroviral therapy (HAART) remains high. It is important to define correlates of mortality in order to improve outcome.

Methods: HIV-1-infected children aged 18 months-12 years were followed up at Kenyatta National Hospital, Nairobi after initiating NNRTI-based HAART. Cofactors for mortality were determined using multivariate Cox regression models.

Results: Between August 2004 and November 2008, 149 children were initiated on HAART of whom 135 were followed for a total of 238 child-years (median 21 months) after HAART initiation. Baseline median CD4% was 6.8% and median HIV-1-RNA was 5.98-log10 copies/ml. Twenty children (13.4%) died at a median of 35 days post-HAART initiation. Mortality during the entire follow-up period was 8.4 deaths per 100 child-years (46 deaths/100 child-years in first 4 months and 1.0 deaths/100 child-years after 4 months post-HAART initiation). On univariate Cox regression, baseline hemoglobin (Hb) <9 g/dl, weight-for-height z-score (WHZ) < -2, and WHO clinical stage 4 were associated with increased risk of death (Hb <9 g/dl HR 3.00 [95% C.I. 1.21-7.39], p = 0.02, WHZ < -2 HR 3.41 [95% C.I. 1.28-9.08], p = 0.01, and WHO clinical stage 4, HR 3.08 [1.17-8.12], p = 0.02). On multivariate analysis Hb < 9 g/dl remained predictive of mortality after controlling for age, baseline CD4%, WHO clinical stage and weight-for-height z-score (HR 2.95 (95% C.I. 1.04-8.35) p = 0.04).

Conclusion: High early mortality was observed in this cohort of Kenyan children receiving HAART, and low baseline hemoglobin was an independent risk factor for death.

Figures

Figure 1
Figure 1
Follow-up and retention in the cohort.
Figure 2
Figure 2
Probability of survival among children receiving HAART.

References

    1. UNAIDS 2008 Report on the Global AIDS Epidemic.
    1. National AIDS and STI Control Programme, Ministry of Health Kenya.
    1. Reddi A, Leeper SC, Grobler AC. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. BMC Pediatr. 2007;7:13. doi: 10.1186/1471-2431-7-13.
    1. Rouet P, Fassinou P, Inwoley A. Long-term survival and immune-virologic response of African HIV-1 infected children to highly active antiretroviral therapy regimens. AIDS. 2006;20(18):2315–9. doi: 10.1097/QAD.0b013e328010943b.
    1. Song R, Jelagat J, Dzombo D. Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya. Pedaitrics. 2007;120(4):e856–61. doi: 10.1542/peds.2006-1122.
    1. Wamalwa D, Farquhar C, Obimbo E. Early response to highly active antiretroviral therapies among HIV-1-infected Kenyan children. J Acquir Immune Defic Syndr. 2007;45:311–317.
    1. Puthanakit T, Oberdorfer A, Akarathum N. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. Clin Infect Dis. 2005;41(1):100–7. doi: 10.1086/430714.
    1. Bolton-Moore C, Mubiana-Mbewe M, Cantrell J. Clinical outcomes and CD4 response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA. 2007;298(16):1888–1899. doi: 10.1001/jama.298.16.1888.
    1. Bong Chin-Nam, Yu Kwong-Leung J, Chiang H. Risk factors for early mortality in children on adult fixed-dose combination antiretroviral therapy in a central hospital in Malawi. AIDS. 2007;21:1805–18. doi: 10.1097/QAD.0b013e3282c3a9e4.
    1. Gortmaker SL, Hughes M, Cervia J. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345:1522–8. doi: 10.1056/NEJMoa011157.
    1. Gibb DM, Duong T, Tookey PA. Decline in mortality, AIDS and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ. 2003;327:1019–24. doi: 10.1136/bmj.327.7422.1019.
    1. Viani R, Araneta M, Deville J. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2004;39:725–31. doi: 10.1086/423178.
    1. Peacock-Villada E, Richardson B, John-Stewart G. Paediatric HAART treatment outcomes: A comparison of developing and developed countries. 16th Conference on Retroviruses and Opportunistic Infections (CROI 2009), Montreal, Canada, February 8-11 2009. Abstract 875.
    1. Violari A, Cotton M, Gibb D. Early Antiretroviral Therapy and Mortality among HIV-1 infected Infants. N Engl J Med. 2008;359:2233–44. doi: 10.1056/NEJMoa0800971.
    1. World Health Organization. Guidelines for the use of Antiretroviral Agents in Paediatrics. World Health Organization Geneva; 2009.
    1. National AIDS and STI Control program (NASCOP) Guideline for antiretroviral therapy in Kenya. Third. Ministry of health, Government of Kenya, Nairobi Kenya; 2005.
    1. World Health Organization. Management of severe malnutrition: a manual for physicians and other senior health workers. World Health Organization Geneva; 1999.
    1. Lutter CK. Iron deficiency in young children in low income countries and new approaches for its prevention, a review. J Nutri. 2008;138:2523–2528. doi: 10.3945/jn.108.095406.
    1. Monitoring the Situation of Children and Women, Statistics by Country, Kenya.
    1. Obimbo E, Mbori-Ngacha DA, Ochieng J. Predictors of early mortality in a cohort of Human Immunodeficiency Virus Type-1 infected African children. Pediatr Infect Dis J. 2004;23:536–543. doi: 10.1097/01.inf.0000129692.42964.30.
    1. Moore RD. Human immunodeficiency virus infection, Anemia and survival. Clin Infect Dis. 1999;29:44–49. doi: 10.1086/520178.
    1. Consolini R, Benviclli W, Legino A. Pre HAART follow-up study of the hematological manifestation in children with prenatal HIV infection, suggestions for reclassification of clinical disease. Italian register for HIV infection in children Pediatr Hematol Oncol. 2007;29:376–383.
    1. Kenya Demographic Health Survey. Central Bureau of Statistics, Nairobi Kenya; 2003.
    1. Marazzi M, Liotta G, Germano P. Excessive Early Mortality in the First Year of Treatment in HIV Type 1-Infected Patients Initiating Antiretroviral Therapy in Resource-Limited Settings. AIDS Res and Hum Retro. 2008;24:555–60. doi: 10.1089/aid.2007.0217.
    1. McMurray DN. Cell-mediated immunity in nutritional deficiency. Prog Food Nutr Sci. 1984;8(3-4):193–228.
    1. Najera O, Gonzalez, Cortes E. Effector T lymphocytes in well-nourished and malnourished infected children. Clin Exp Immunol. 2007;148(3):501–6.
    1. Najera O, Najera O, Gonzalez, Toledo. Flow cytometry study of lymphocytes in malnourished and well-nourished children with bacterial infections. Clin Diag Lab Immunol. 2004;11(3):577–80.
    1. Fassinou P, Elenga N, Rouet F. Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Cote d'Ivoire. AIDS. 2004;18:1905–13. doi: 10.1097/00002030-200409240-00006.
    1. Smith K, Kuhn L, Coovadia. Immune reconstitution inflammatory syndrome among HIV-infected South African infants initiating antiretroviral therapy. AIDS. 2009;23:1097–1107. doi: 10.1097/QAD.0b013e32832afefc.
    1. Pairoj R, Wongpraparut, Jacobs LE. Cardiac Manifestations of Acquired Immunodeficiency Syndrome. Arch Intern Med. 2000;160:602–608. doi: 10.1001/archinte.160.5.602.
    1. Dau B, Holodniy M. The relationship between HIV infection and Cardiovascular disease. Curr Cardiol Rev. 2008;4:203–218. doi: 10.2174/157340308785160589.
    1. Martinez E, Larrousse M, Gatell J. Cardiovascular disease and HIV infection: host, virus, or drugs? Curr Opin Infect Dis. 2009;22:28–34. doi: 10.1097/QCO.0b013e328320a849.
    1. World Health Organization, Geneva Switzerland. Antiretroviral therapy of HIV infection in infants and children in resource-limited settings: towards universal access. Recommendations for a public health approach. World Health Organization, Geneva; 2006.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj